louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04759300: Effectiveness of C-MAC Video-stylet Versus C-MAC D- Blade Video-laryngoscope for Tracheal Intubation
Official title: Effectiveness of C-MAC Video-stylet Versus C-MAC D- Blade Video-laryngoscope for Tracheal Intubation in Patients With Predicted Difficult Airway: Randomized Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Difficult Mask Ventilation
Difficult Intubation
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2021-02-18
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The patients will be randomly assigned into two equal groups using computer-generated randomization technique. Group C-MAC VS (VS group) included patients undergoing tracheal intubation using the C-MAC VS. Group C-MAC VL D -blade (D group) included patients undergoing intubation using the C-MAC VL D-blade.
Primary purpose: DIAGNOSTIC

Brief summary: Videolaryngoscopy provides a better laryngeal view and do not need airway alignment for tracheal intubation.

Detailed description: The C-MAC-VS can be connected easily to the same C- MAC monitor and Pocket Monitor without requiring any additional light source and camera. This device is great for cases with limited mouth opening, airway obstruction and difficult intubation. C-MAC-VS has no lumens so it's very easy to clean and it can accommodates a size ETT 6.0 and greater.

Eligibility criteria: Inclusion Criteria:

* patients with BMI ≥ 30 kg/m2,
* presence of any predictors of difficult intubation;
* Mallampati score \> =3;
* inter-incisor distance \< 3 cm;
* thyromental distance \< 6 cm;
* neck extension \< 80°from neck flexion;
* cervical spine instability; history of difficult endotracheal intubation or difficult mask ventilation

Exclusion Criteria:

* patients have increased risk of pulmonary aspiration;
* have significant medical diseases in term of cardiac, respiratory, hepatic, renal

Primary outcomes:
measure: duration of intubation procedure
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: rehab Abd Elaziz
Study officials:
affiliation: Alexandria University
name: rehab A. Abd Elaziz, Ass.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05426200: Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
Official title: Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lung Transplant
Keywords: Self-management
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 230
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To examine the effectiveness of an individual health coaching intervention for lung transplant candidates. This intervention will include up to 12 health coaching sessions via phone call over a 12-16 week period. This will be compared to a usual care group the receives pre-transplant care and education alone.


Eligibility criteria: Inclusion Criteria:

* Waitlisted or deferred for lung transplantation at Mayo Clinic Rochester, Mayo Clinic Florida, or University of Washington

Exclusion Criteria:

* Under 18 years old
* Non-English speaking, nonverbal, or extremely hard of hearing

Primary outcomes:
measure: Change in Score on Chronic Respiratory Disease Questionnaire (CRQ) Mastery Subdomain
timeFrame: Baseline, 12-16 Week Follow-up
measure: Change in Score on Chronic Respiratory Disease Questionnaire (CRQ) Emotional Function Subdomain
timeFrame: Baseline, 12-16 Week Follow-up
Secondary outcomes:
measure: Post-Transplant Quality of Life Chronic Respiratory Disease Questionnaire (CRQ) Composite
timeFrame: Post-Transplant Follow-up, on Average 1 Year
measure: Intervention Feasibility and Acceptability via Qualitative Surveys and Interviews
timeFrame: 12-16 Week Follow-up
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: Mayo Clinic
name: Cassie C Kennedy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00371800: The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes
Official title: The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Type 1 Diabetes Mellitus
Keywords: Cinnamon
Type 1 Diabetes
Adolescent
HbA1c
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: Dartmouth College
First posted: 2006-09-04
Enrollment: 72
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the purpose of this study is to determine if cinnamon improves glucose control among adolescents with type 1 diabetes mellitus.

Detailed description: Widespread achievement of glucose control remains an elusive goal for adolescents with Type 1 diabetes. Previous research has suggested that cinnamon may be effective at improving glucose control in type 2 diabetes. To date, no research has investigated the effect of cinnamon on type 1 diabetics. If the addition of a simple, natural, pill to a standard insulin regimen can significantly improve glucose control, the clinical implications would be substantial.

Comparison: Using a prospective, double-blind, placebo-controlled design, 72 adolescent type I diabetics were treated with cinnamon (1 gram/day) or an equivalent appearing placebo for 90 days. HbA1c, total daily insulin intake, and adverse events were recorded and compared between groups.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of Type 1 diabetes for \> 18 months prior to enrollment,
2. Age 13-18 years at the time of enrollment
3. Presenting to the clinic for routine care,
4. No hospital admissions for medical or psychiatric reasons in the 12 months prior to enrollment,
5. Accessible by phone,
6. Not pregnant.

Exclusion Criteria:

(1) Pregnant

Primary outcomes:
measure: HbA1c
Secondary outcomes:
measure: Total Daily Insulin
measure: Carbohydrate/insulin dose
measure: Hypoglycemic events
measure: Compliance
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Samuel J Casella, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05548400: Energy and Protein Adequacy of Oral Intake After Ventilator Withdrawal Among Critically Ill Patients.
Official title: Energy and Protein Adequacy of Oral Intake After Ventilator Withdrawal Among Critically Ill Patients.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critical Illness
Nutritional Imbalance
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult critically ill patients admitted in the intensive care unit of a general university hospital in southern Brazil.

Brief summary: The aim of this study is to evaluate the adequacy of exclusive oral intake, in terms of energy-protein amount, after extubation in critically ill patients who remained on invasive mechanical ventilation for at least 48 hours.

Detailed description: A prospective observational study. The adequacy of exclusive oral consumption will be assessed in a consecutive sample of critically ill patients after ventilator removal by visual intake scale in 0%, 25%, 50%, 75%, or 100% of principal meals, i.e., lunch and dinner, during seven days after recruitment.

To characterize the study population, general characteristics of patients and their hospital outcomes will be collected: sociodemographic (age, sex, ethnicity, education) and admission clinical data (weight, height, Simplified Acute Physiology Score 3, Nutritional Risk Screening, and Subjective Global Assessment), energy and protein intake within 72 hours after initiation of invasive mechanical ventilation, the underlying disease that led to hospitalization, length of stay in the ICU, length of invasive mechanical ventilation and hospital stay, the incidence of infections after ICU discharge and in-hospital death.

Eligibility criteria: Inclusion criteria:

* Adult critically ill patients
* Mechanical ventilation for at least 48 hours and who migrate to exclusively oral feeding within seven days after extubation without receiving complementary parenteral or enteral nutrition.
* Admitted to the ICU in Hospital de Clínicas de Porto Alegre from March 2022 to October 2022.

Exclusion criteria:

* Pregnancy
* Occurrence of major abdominal surgery during ICU stay
* Tracheostomized patients
* Patients unable to start an oral diet after extubation.
* Patients previously included in the study.
* Patients seeking exclusive palliative care

Primary outcomes:
measure: Adequacy of oral intake after extubation on critical ill patients
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
state: Rio Grande Do Sul
Study officials:
affiliation: HCPorto Alegre
name: Juliana P Antonio, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06424600: Ginglival Health Among Smokers Visiting Dental Hospital
Official title: Effect of Various Forms of Nicotine Consumption on Gingival Health of Dental Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking
Keywords: Gingival
Smokers
Lead sponsor: Pakistan Institute of Medical Sciences
Sponsor class: OTHER_GOV
First posted: 2024-05-22
Enrollment: 300
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients visiting Dental Outpatient Department with history of Smoking

Brief summary: The effect of different forms of nicotine intake on the gingival health of dental patients that visited a public sector in Islamabad. A total of 300 dental patients that visited School of Dentistry, Islamabad voluntarily participated in this study. The nicotine consuming participants involved in this study were Smoke-form users, E cigarette-form users, and Dual-form users whose Gingival Index (G-I) was inspected to demonstrate an association between their smoking type and duration of developing severe gingivitis.

Detailed description: A total of 300 dental patients who visited the School of Dentistry, Islamabad, participated voluntarily in this study. The nicotine-consuming participants involved in this study were Smoke-Form users (S-form), Electronic cigarette-form users (E-form), and Dual-Form users (D-form) whose Gingival Index (G-I) was inspected to demonstrate an association between their smoking type and duration of developing severe gingivitis. The G-I ranging between 0.5 - 2.00 was used to calculate the occurrence of severe gingival issues in participants with smoking habits where G-I between 0.50 1.00 displayed Light gingival inflammation, G-I between 1.10-2.00 revealed Moderate gingival inflammation and G-I \> 2.00 confirmed Severe gingival inflammation. A chi-Square test was used for the association by keeping significance p\< 0.05.

Eligibility criteria: Inclusion Criteria:

* Smokers with good general health status visiting dental hospital

Exclusion Criteria:

* Non-smoker dental patients

Primary outcomes:
measure: Gingival Index
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Afsheen Mansoor
Study officials:
affiliation: Pakistan Institute of Medical Sciences
name: Afsheen Mansoor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tomar SL, Hecht SS, Jaspers I, Gregory RL, Stepanov I. Oral Health Effects of Combusted and Smokeless Tobacco Products. Adv Dent Res. 2019 Oct;30(1):4-10. doi: 10.1177/0022034519872480.
Clinical trial NCT00328900: Measurement of Stress During Anesthesia With "Pain Detector" on Patients Receiving Atropine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hemorrhoids
Fissure in Ano
Keywords: Galvanic skin response
Anesthesia
Atropine
Lead sponsor: Rikshospitalet University Hospital
Sponsor class: OTHER
First posted: 2006-05-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: 24 patients randomly divided into two groups, one of the groups receiving atropine in addition to the planned anaesthesia. Skin conductance parameters to be compared between the two groups.

Detailed description: Skin conductance (SC), in terms of numbers of skin conduction fluctuations (NSCF), amplitude and mean skin conductance level, reflect the activity in the sympathetic postganglionic cholinergic fibers which innervate the palmar and plantar sweat glands. Skin conductance, especially numbers of skin conductance fluctuations, may be a promising tool to monitor anesthesia. Atropine, an anticholinergic agent, acts as an antagonist on the muscarinic receptors of the sweat glands and inhibits their secretion in a dose-dependent way. The aim of this study was to find out to what degree SC is influenced by i.v. administration of atropine.

Study hypothesis: SC is not influenced by i.v. administration of atropine.

Eligibility criteria: Inclusion Criteria:

* Patients in ASA-group 1-2
* Operations (anal fissures, anal fistulas and haemorrhoids) lasting for less than one hour
* informed consent
* BMI \<30

Exclusion Criteria:

* Patients using any medication known to influence the autonomous nervous system
* Patients with contraindications to atropine (e.i. fibrillation, glaucoma ect)
* BMI \>30
* Pregnancy

Primary outcomes:
measure: Number of skin conductance fluctuations
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Ulleval University Hospital
Study officials:
affiliation: Rikshospitalet University Hospital
name: Hanne Storm, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01774500: Biomarkers In Seizure To Predict Recurrence and Severe Outcomes
Official title: Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Seizures
S-100b Protein
Copeptin
Keywords: biomarkers
Emergency Department
Seizures
epilepsy
S100b
copeptin
Lead sponsor: Bistro Study Group
Sponsor class: OTHER
Collaborators: name: Groupe Hospitalier Pitie-Salpetriere
name: Barts & The London NHS Trust
First posted: 2013-01-24
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency department patients

Brief summary: We study the hypothesis that combination of Proteine S100 beta and Copeptin within normal ranges can rule out seizure recurrences and severe outcome, and allow early discharge from the emergency department

Detailed description: Prospective study for a 12 month period in Paris (France) and London (UK).

Inclusion criteria :

* seizure within 24h of attendance to an Emergency department (ED)
* or seizure in the ED

Exclusion Criterie :

* pregnancy
* prisoneer

Primary endpoint :

- recurrence of seizure, hospitalisation more than 24 hours or death within seven days

Secondary endpoint :

* Hospital free days at day 7 and day 28
* Death, ICU admission, or neurosurgical intervention at day 7 and day 28
* Return visit to the ED or re admission at day 7 and day 28

data collection:

* demographics
* past medical history, medication
* vital signs (Heart rate, temperature, Pulse oxymetry, blood pressure, GCS) on arrival
* Pathology (White cell count, Sodium, Calcium, Glucose, lactate)
* Protein S100B and Copeptin
* Seizure characteristics (Witnessed, simple, partial, complex, provoked, acute symptomatic, idiopathic)
* Discharge plan, outcomes

Follow up at day 7 and day 28, hospital visit or phone call

Eligibility criteria: Inclusion Criteria:

* Seizure within 24 hours of ED attendance
* Or Seizure in the ED

Exclusion Criteria:

* Pregnancy
* Prisoner
* age \< 18 years old

Primary outcomes:
measure: Combined hospital admission, seizure recurrence, or death at day 7
timeFrame: 7 days
Secondary outcomes:
measure: Hospital free days
timeFrame: 7 days
measure: Hospital free days
timeFrame: day 28
measure: death or ICU admission
timeFrame: day 7
measure: Death or ICU admission
timeFrame: 28 days
measure: Recurrence of seizure
timeFrame: 7 days
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Lariboisiere
city: Paris
country: France
facility: Groupe Hospitalier pitie-salpetriere
city: Paris
country: France
facility: Hopital Tenon
city: London
country: United Kingdom
facility: Royal London Hospital, Barts Health NHS Trust
Study officials:
References:
Clinical trial NCT02330900: Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators
Official title: Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Electromagnetic Interference
Keywords: Implantable cardioverter defibrillator
Electromagnetic interference
Cell phone
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2015-01-05
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Evaluation of electromagnetic interference between modern cell phones and contemporary implantable cardioverter defibrillators (ICDs)

Detailed description: Electrograms of ICDs will be analyzed during wireless telemetry and during exposure to an activated cell phone. ICD therapy will have been temporarily inactivated before exposure to cell phones to avoid inappropriate shocks, and the sensitivity level of the ICD will be set to maximum. The cell phones will be held over the ICD generator, as well as in the parasternar region (close to the ICD lead, which senses the signals).

Interference will be assessed by the presence of visible artefacts on the real-time electrogram, with ICD marker annotations showing atrial and/or ventricular sensed episodes. The outcome measure will be the number and proportion of patients who have electromagnetic interference of the ICD when exposed to cell phones.

The procedure will take approximately 5-10minutes, with reprogramming of the device at the end of the test. No further follow-up in the context of the study will be performed.

Eligibility criteria: Inclusion Criteria:

* Implantation with a wireless-enabled ICD

Exclusion Criteria:

* Age \<18yrs
* inability to sign an informed consent
* pacemaker dependancy

Primary outcomes:
measure: Number of patients who have electromagnetic interference of the ICD when exposed to cell phones.
timeFrame: 5-10minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: University Hospital Geneva
state: GE
Study officials:
affiliation: University Hospital, Geneva
name: Haran Burri, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Burri H, Mondouagne Engkolo LP, Dayal N, Etemadi A, Makhlouf AM, Stettler C, Trentaz F. Low risk of electromagnetic interference between smartphones and contemporary implantable cardioverter defibrillators. Europace. 2016 May;18(5):726-31. doi: 10.1093/europace/euv374. Epub 2016 Feb 8.
Clinical trial NCT05522400: Development and Application of Virtual Reality (VR) and Human Computer Interaction System in the ICU Patients
Official title: Virtual Reality (VR) and Human Computer Interaction System in the Early Stage of ICU Patients Development and Application of Rehabilitation Exercise
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rehabilitation Exercise of ICU Patients
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2022-08-31
Enrollment: 244
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: By developing of VR and human computer interaction system of early rehabilitation exercise for ICU patients, this project aims to construct virtual scenes and realize the interaction between ICU patients and virtual scenes during active rehabilitation training for critically ill patients in long-term bed. This project can increase the patient's willingness to exercise rehabilitation, improve the training effect and improve clinical outcomes in critically ill patients.


Eligibility criteria: * Inclusion Criteria:

  * Over 18 years of age
  * Voluntary participation
* Exclusion Criteria:

  * Unable to walk independently before admission to ICU;
  * High dose of vasoactive drugs to maintain vital signs;
  * Acute stroke;
  * Upper limb fractures or amputations;
  * Patients with spinal fracture or pathological fracture;
  * Patients who have been hospitalized for 30 days or more before admission to ICU;
  * Plan to move out of ICU within 24 hours; In palliative care

Primary outcomes:
measure: incidence of the ICU-acquired asthenia
timeFrame: up to 2 weeks
measure: Average daily physical activity time
timeFrame: up to 2 weeks
measure: length of ICU stay
timeFrame: up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: 180 Fenglin Road
Study officials:
affiliation: Fudan University
name: Wenyan PAN
role: PRINCIPAL_INVESTIGATOR
References: